and patent cost write-off 380 377 1,087 1,170
Interest and bank charges 26 21 150 65
-------------------------------------------------------------------------
15,566 17,850 55,706 52,333
-------------------------------------------------------------------------
Net loss before
undernoted items (15,265) (17,156) (54,461) (50,190)
Interest income 1,021 429 2,585 1,503
Accretion expense (1,452) - (14,568) -
Change in fair value of
derivative-related asset 972 - (898) -
Foreign exchange gain (loss) 565 (24) 1,184 (525)
Other income 270 545 987 1,066
Share of loss in a company
subject to significant
influence - (452) (327) (1 951)
Non-controlling interest - 149 109 639
-------------------------------------------------------------------------
Net loss ($13,889) ($16,509) ($65,389) ($49,458)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net loss per share:
Basic and diluted ($0.29) ($0.43) ($1.54) ($1.28)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average number
of common shares
outstanding 47,495,376 38,814,360 42,360,279 38,589,402
-------------------------------------------------------------------------
-----------------
'/>"/>
| SOURCE NEUROCHEM INC. Copyright©2007 PR Newswire. All rights reserved |